Hence, identifying the specific cell types and mechanisms by which progranulin acts both centrally and peripherally to curb or exacerbate inflammation and associated pathology could provide critical insights for developing effective immunomodulatory therapeutic strategies to prevent or treat FTD-GRN and other neuroinflammatory neurodegenerative conditions. The gene discussed is GRN; the disease is frontotemporal dementia.